Rates of serious adverse events , including heart failure ( 3.4 % for aleglitazar vs 2.8 % for placebo , P = .14 ) , gastrointestinal hemorrhages ( 2.4 % for aleglitazar vs 1.7 % for placebo , P = .03 ) , and renal dysfunction ( 7.4 % for aleglitazar vs 2.7 % for placebo , P < .001 ) were increased .